SLC5A2 and diabetes mellitus: Furthermore, in the EMPA-REG OUTCOME trial, compared with those allocated to placebo, albuminuria remained lower among those allocated to empagliflozin about 1 month after stopping study treatment, suggesting that SGLT-2 inhibition prevented diabetes-related structural changes in the kidney (although this hypothesis has not been tested by kidney biopsy studies) [44].